Robust and high-yielding platform process for plasmid DNA production
How Syngene scientists developed a platform process for plasmid DNA production with high titers of > 1 g/L upstream with >25% recovery downstream.
Process development and scale-up of highly challenging biomolecules
Three case studies on downstream platform process development for antibody fragments, three broadly neutralizing antibodies (bNAbs) against HIV, and a new class of regenerative implant used for treating a degenerative disease.
Mycoplasma Contamination Detection in Biopharmaceuticals
Presenting impact of Mycoplasma contamination, available testing methods, and why Syngene prefers NAT-based Mycoplasma detection method over other methods.
How Syngene’s ‘first-time right’ process advanced a novel vascular calcification inhibitor API from Lab-scale to Tox-batch manufacturing successfully
Learn how Syngene supported a pharma company in developing and manufacturing lab-scale and later Tox batches of its target molecule through an improved synthesis route. All this while meeting chemical purity requirements of >98%.
Holistic Target Identification and Validation services
Syngene’s Target Identification and Validation services combine data, informatics, and knowledge about biological target assays for holistic target assessment and risk mitigation in drug discovery.
ADME/PK profiling capabilities
Syngene, with its comprehensive suite of DMPK profiling assays, can help you achieve a high rate of success with your clinical candidates across drug modalities.
Choosing the ‘right’ CRO-CDMO in Biopharma – What has changed
Learn the new criteria that have emerged as more important for selecting an outsourcing partner consequent to disruptions caused by the COVID-19 pandemic.
How Syngene is implementing Green Chemistry in pharmaceutical development – Design to Delivery
Learn how Syngene is helping pharma companies minimize environmental impact using its Green Chemistry approach to drug development.
How Syngene synthesized a complex cyclic peptide for use in novel drug therapies
Learn how Syngene’s novel approach helped synthesize a complex 11-mer cyclic peptide for use in drug therapies.
How Syngene delivered pre-IND to IND Safety studies for a leading biotech company in just three months
Learn how Syngene partnered with a biotech company to deliver pre-IND to IND Safety studies in just three months for a treatment therapy for gut-brain diseases.